

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**927**

---

# **WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION**

---

Fifty-fourth report



**World Health Organization**

**Geneva 2005**

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on Biological Standardization (2003 : Geneva, Switzerland)  
WHO Expert Committee on Biological Standardization : fifty-fourth report.

(WHO technical report series ; 927)

1.Biological products — standards 2.Vaccines — standards 3.Blood  
4.Reference standards 5.Guidelines I.Title II.Series

ISBN 92 4 120927 5  
ISSN 0512-3054

(LC/NLM classification: QW 800)

WHO Expert Committee on Biological Standardization

© World Health Organization 2005

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to Publications, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

**Typeset in Hong Kong  
Printed in Singapore**

# Contents

Introduction	1
General	1
Developments in biological standardization	1
Progress reports and work programmes	5
Contamination of oral poliomyelitis vaccine with wild poliovirus	7
Feedback from the field on WHO recommendations and guidelines and capacity building in quality assurance	8
International guidelines, recommendations and other matters related to the manufacture and quality control of biologicals	9
Guidelines on nonclinical evaluation of vaccines	9
Recommendations for the production and control of pneumococcal conjugate vaccines	9
Recommendations for the production and control of influenza vaccine (inactivated)	10
Requirements for the use of animal cells as <i>in vitro</i> substrates for the production of biologicals	11
Requirements for diphtheria, tetanus and pertussis and combined vaccines	11
Potency assays for acellular pertussis vaccines	12
Requirements for the collection, processing and quality control of material for transplantation	13
Human and animal spongiform encephalopathies and safety of biologicals	13
Gene transfer medical products	14
Proposals for discontinuation of international requirements and guidelines	14
International reference materials	15
Proposal for discontinuation of reference materials	15
Recommendations for the preparation, characterization and establishment of international and other biological reference materials	15
Antibodies	17
Anti-toxoplasma serum, human	17
Antigens and related substances	17
Smallpox reference materials	17
Yellow fever vaccine	18
Pertussis toxin	19
Diphtheria and tetanus reference materials	19
Blood products and related substances	20
Factor VIII, concentrate	20
Factor VIII/von Willebrand factor, plasma	21
Low-molecular-weight heparin	21
Prekallikrein activator	22

<b>Cytokines, growth factors and endocrinological substances</b>	22
WHO consultation on cytokines, growth factors and endocrinological substances	22
Human interferon beta	23
Tumour necrosis factor alpha, human	24
Luteinizing hormone, recombinant	24
Thyroid-simulating hormone for immunoassay	25
Interferon neutralizing antibody tests	26
<b>Diagnostic reagents</b>	26
WHO consultation on international standards for testing diagnostic kits used in detection of hepatitis B surface antigen and anti-hepatitis C virus antibodies	26
Hepatitis B surface antigen	27
Lipoprotein (a)	29
<b>Miscellaneous</b>	29
Standardization of human papilloma virus vaccine	29
Standardization of human immunodeficiency virus neutralizing antibody assays	30
<b>Annex 1</b>	
<b>WHO guidelines on nonclinical evaluation of vaccines</b>	31
<b>Annex 2</b>	
<b>Recommendations for the production and control of pneumococcal conjugate vaccines</b>	64
<b>Annex 3</b>	
<b>Recommendations for the production and control of influenza vaccines (inactivated)</b>	99
<b>Annex 4</b>	
<b>Requirements for the use of animal cells as in vitro substrates for the production of biologicals (Addendum 2003)</b>	135
<b>Annex 5</b>	
<b>Recommendations for diphtheria, tetanus, pertussis and combined vaccines (Amendments 2003)</b>	138
<b>Annex 6</b>	
<b>Biological substances: international standards and reference reagents</b>	148
<b>Annex 7</b>	
<b>Recommendations and guidelines for biological substances used in medicine and other documents</b>	151

# WHO Expert Committee on Biological Standardization

Geneva, 17–21 November 2003

## Members

- Dr W.G. van Aken, Amstelveen, the Netherlands (*Chairman*)  
Dr D.H. Calam, Pewsey, Wiltshire, England (*Rapporteur*)  
Dr M. de los Angeles Cortes Castillo, Director, Quality Control, National Institute of Hygiene, Mexico City, Mexico  
Dr R. Dobbelaer, Head, Biological Standardization, Scientific Institute of Public Health, Brussels, Belgium (*Vice-Chairman*)  
Dr F. Fuchs, Director, Lyon Site, French Agency for Safety of Health Products, Lyon, France  
Dr B. Kaligis, International Relations Division Head, Bio Farma, Bandung, Indonesia  
Dr N.V. Medunitsin, Director, Tarasevic State Institute for the Standardization and Control of Medical Biological Preparations, Moscow, Russian Federation  
Dr F. Ofosu, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada  
Dr F. Reigel, Head, Biological Medicines and Laboratories, Swissmedic, Agency for Therapeutic Products, Berne, Switzerland

## Representatives of other organizations

### *Developing Country Vaccine Manufacturer's Network*

- Dr S. Jadhav, Executive Director (Quality Assurance), Serum Institute of India Ltd., Maharashtra, Pune, India

### *European Diagnostic Manufacturers Association*

- Dr J. Diment, Scientific and Technical Manager, North Europe, Asia Pacific and Export, Ortho-Clinical Diagnostics, Amersham, England

### *Council of Europe, European Directorate for the Quality of Medicines*

- Mr J.-M. Spieser, Head, Division IV Biological Standardisation/Network of Official Medicines Control Laboratories (OMCLs), Strasbourg, France

### *International Association of Biologicals*

- Dr A. Eshkol, Senior Scientific Adviser, Aeres Sero International SA, Geneva, Switzerland

### *International Federation of Clinical Chemistry and Laboratory Medicine*

- Professor J. Thijssen, c/o Department of Endocrinology, University Hospital Utrecht, Utrecht, the Netherlands

### *International Federation of Pharmaceutical Manufacturers Associations*

- Dr M. Duchêne, Director, Quality Control, GlaxoSmithKline Biologicals, Rixensart, Belgium

- Dr A. Sabouraud, Director, Quality Control of Development Products, Aventis Pasteur S.A., Marcy l'Etoile, France

### *International Society on Thrombosis and Haemostasis*

- Professor I.R. Peake, Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield, England

*Plasma Protein Therapeutics Association*

Dr E. Hutt, Brussels, Belgium

*United States Pharmacopeia*

Dr T. Morris, Department of Information and Standards Development, Rockville, MD, USA

## **Secretariat**

Dr T. Barrowcliffe, Head, Division of Haematology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr A. Bristow, Head, Division of Endocrinology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr M. Corbel, Head, Division of Bacteriology, Division of Bacteriology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr R. Decker, Hepatitis and AIDS Research, Deerfield, Illinois, USA (*Temporary Adviser*)

Dr W. Egan, Acting Director, Office of Vaccines, Center for Biologics, Evaluation and Research, Food and Drug Administration, Rockville, MD, USA (*Temporary Adviser*)

Dr J. Epstein, Director, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD, USA (*Temporary Adviser*)

Dr I. Feavers, Division of Bacteriology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr E. Griffiths, Associate Director General, Biologics and Genetic Therapies, Ottawa, Ontario, Canada (*Temporary Adviser*)

Dr M.F. Gruber, Scientific Reviewer, Division of Vaccines and Related Products Application, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD, USA (*Temporary Adviser*)

Dr S. Inglis, Director, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr L. Jodar, Associate Director for Programmes, Institutional Development and Partnerships, International Vaccine Institute, Kwanak-Ku, Seoul, Republic of Korea (*Temporary Adviser*)

Dr N. Lelie, Viral Quality Control Unit, Sanquin-CLB, Alkmaar, the Netherlands (*Temporary Adviser*)

Dr P.D. Minor, Head, Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr M. Nübling, Paul Ehrlich Institute, Langen, Germany (*Temporary Adviser*)

Dr J. Wood, Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr D. Wood, Coordinator, Quality Assurance and Safety of Biologicals, World Health Organization, Geneva, Switzerland (*Secretary*)

## **Introduction**

The WHO Expert Committee on Biological Standardization met in Geneva from 17 to 21 November 2003. The meeting was opened by Dr Vladimir Lepakhin, Assistant Director-General, Health Technology and Pharmaceuticals, WHO, on behalf of the Director-General.

Dr Lepakhin emphasized the importance to Member States of the work of the Committee in preparing recommendations for biological products and for the development, establishment and distribution of reference materials for biologicals. During the meeting, a number of proposals for reference materials and draft recommendations would be considered. Dr Lepakhin informed the Committee that the World Health Assembly had endorsed many resolutions on the subjects of quality, safety and efficacy of medicines, blood products, vaccines and other biologicals. Despite considerable progress made both by WHO and its Member States in the implementation of such directives, urgent action was needed to sustain and expand basic normative regulatory functions underpinning public health efforts to assure access to quality biological medicines. Furthermore, as a result of rapidly changing global environments, increased international trade and the opening of borders, many biological medicines, including blood products, were circulating more freely than ever. Unless they were subject to control, biological medicines such as those derived from blood and plasma could be vehicles for the transmission of infectious diseases and/or other emerging agents. Dr Lepakhin reminded the Committee that the establishment and functioning of national regulatory systems with reference to WHO recommendations, norms and standards was essential to protect patients and public health from fraudulent practices and economic waste. WHO was therefore seeking political commitment and support from Member States to sustain and increase capacity building and training in all aspects of regulatory functions, including the efficient implementation of good regulatory practices. Finally, Dr Lepakhin reminded the Committee that its decisions should be based on sound science and common sense and not on partisan considerations.

## **General**

### **Developments in biological standardization**

The Committee was informed of the organizational changes that had taken place at WHO headquarters. The two teams concerned with

biological standardization work on an integrated programme although based in different clusters. The outcomes of the standardization programme include recommendations for quality standards, provision of reference materials, development of consensus on quality-related issues for biologicals and building technical capacity for biologicals in the different WHO Regions. The role of the International Laboratories in the development of this programme was acknowledged. The plans for further development of laboratory support for biological standardization by broadening geographical representation and improving working relationships with existing laboratories through regular meetings and better definition of priorities were outlined. A review of the Expert Advisory Panel on Biological Standardization had shown the need for more even geographical and gender representations and for the identification of more experts currently working the field. The need to enhance support for the Expert Committee had also been recognized and this could usefully be addressed through the greater use of Working Groups to prepare and review proposals for reference materials and recommendations. Consideration was also being given to how the work and operation of the Expert Committee might evolve to meet future needs in a more timely and efficient manner.

The place of standardization of vaccines within the Immunization, Vaccines and Biologicals department was outlined. Establishment of norms and standards is a critical early stage in the development of new vaccines. There is increasing appreciation by users of the norms and standards of the impact of standardization on global public health and trade, leading to increased support, both in terms of financial and human resources, and also to increased demand for standardization activities. These demands are likely to require innovative ways of providing support. As an example, the generous support of the Government of the Republic of Korea, through staff secondment from the Korean Food and Drug Administration, was acknowledged. The priorities for vaccine standardization for the next 2 years had

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29987](https://www.yunbaogao.cn/report/index/report?reportId=5_29987)

